Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 96NIH 8NETWORK 5INDUSTRY 3FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Rare Diseases 1Oligodendroglioma 1Glioma 1Glioblastoma 1Genetic Diseases, Inborn 1Brain Neoplasms 1Astrocytoma 1

Interventions

pembrolizumab 3enzalutamide 3Abiraterone Acetate 3apalutamide 2Topotecan 2Testosterone 2Itraconazole 2Docetaxel 2Cholecalciferol 2Celecoxib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zanubrutinib 1venetoclax 1talabostat 1sargramostim 1pasireotide 1olaparib 1leucoselect phytosome 1ibrutinib 1capivasertib 1acalabrutinib 1abiraterone 1Tablets 1Streptozocin 1Rituximab 1Radiosurgery 1Pluvicto 1PT-100 dipeptide 1Oxaliplatin 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × FED × Carmustine × Clear all
NCT00004688 2015-03-25

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

FDA Office of Orphan Products Development

Phase 2 Completed
35 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Genetic Diseases, Inborn, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡